Abstract Body

Background

Long COVID (LC) affects at least 5% of individuals following acute SARS-CoV-2 infection, translating to more than 400 million cases globally. Among the proposed mechanisms underlying LC pathogenesis, viral persistence has garnered increasing attention. Persistent detection of SARS-CoV-2 antigens in plasma has been reported up to 12 months post-infection, suggesting ongoing viral activity or antigenic stimulation. However, the temporal kinetics and longitudinal evolution of antigenemia remain poorly characterized, as most studies to date have relied on cross-sectional designs or single time-point assessments.

Methods

We conducted a 2-year longitudinal study involving 425 adults: 167 with LC, 148 fully recovered from acute COVID-19, and 110 uninfected controls.  Plasma samples were collected at 6–12 months (n=330; Visit 1) and 18–24 months post-infection (n=304; Visit 2). SARS-CoV-2 spike, S1 subunit, and nucleocapsid antigens were quantified using the ultra-sensitive Simoa® platform blinded for clinical features.  Serological profiling included in-house ELISA-based detection of anti-S2+RBD antibodies, as well as isotype-specific responses (IgG, IgA, IgM) and neutralizing antibody titers against WH1. All samples classified as uninfected were seronegative for anti-N antibodies (in-house ELISA).

Results

In visit 1, Spike antigenemia was detected in 26 subjects with LC (19.8%), 23 individuals from the recovered group (16%), and 2 uninfected subjects (3.6%). In visit 2, Spike antigenemia was only detectable in 2 subjects with LC (1.4%) and 1 uninfected individual (1.5%). S1 antigenemia was present in visit 1 in 5 LC patients (3.8%), 3 recovered individuals (2.1%) and was undetectable in the uninfected group (Figure 1). S1 antigenemia was undetectable by visit 2 in all groups. N antigenemia was detected in visit 1 in 9 LC patients (6.9%), 4 recovered individuals (2.8%), and 1 uninfected individual (1.8%). In visit 2, it remained detectable only in 3 LC patients (2.1%).  Antigenemia was not associated with number or type of persistent symptoms, antibody titers, including neutralizing capacity, or vaccination status.

Conclusions

SARS-CoV-2 antigenemia can be detected between 6 and 12 months after the acute Covid-19 episode in roughly one fifth of subjects with LC but also at similar frequency in individuals who recover from acute Covid-19. However, by two years post-infection, only a very small number of individuals remain positive. 

Table or Figure